Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NKTXthis companyNkarta, Inc.	$1.44	-1.31×	0.44×	0×	-1.83×	-132.8%	0.0%	0.0%	0.0%	-33.3%	-31.2%	-65.7%	0.24×	-0.39×	0×	12.69×	0.0%	1	-2.81	2	C
ALECAlector, Inc.	$2.40	-1.12×	5.24×	7.63×	-0.99×	-108.0%	54.1%	-692.8%	-679.2%	-466.3%	-62.5%	-114.6%	1.18×	0.22×	0×	3.83×	0.0%	2	-7.33	2	C
ELTXElicio Therapeutics, Inc.	$1.63	-3.09×	74.5×	0×	-3.16×	-85.8%	0.0%	0.0%	0.0%	-2418.8%	-201.0%	-30.3%	8.87×	0.11×	-33.29×	2.38×	0.0%	2	-14.29	1	D+
FATEFate Therapeutics, Inc.	$1.93	-0.85×	0.56×	17.56×	-1.16×	-121.9%	-94.1%	-2222.4%	-2051.1%	-65.8%	-51.4%	-96.0%	0.38×	-0.25×	0×	5.79×	0.0%	3	-8.27	1	C-
PEPGPepGen Inc.	$2.47	-3.07×	1.86×	0×	-2.62×	-56.9%	0.0%	0.0%	0.0%	-60.8%	-56.9%	-29.8%	0.12×	0.49×	0×	11.94×	0.0%	2	-0.25	2	C+
VORVor Biopharma Inc.	$20.33	-0.19×	-0.79×	0×	0.38×	104.7%	0.0%	0.0%	0.0%	423.6%	-84.6%	-111.3%	-0.02×	0.57×	0×	18.2×	0.0%	3	6.9	3	B
Peer median	—	-1.12×	1.86×	0×	-1.16×	-85.8%	0.0%	0.0%	0.0%	-65.8%	-62.5%	-96.0%	0.38×	0.22×	0×	5.79×	0.0%	2	-7.33	2	—